CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Optipharm Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Optipharm Co Ltd
63, Osongsaengmyeong 6-ro
Osong-eup, Heungdeok-gu
Phone: +82 432497500p:+82 432497500 CHEONGJU, 28158  South Korea Ticker: 153710153710
Business Summary
Optipharm.CO.,LTD is a Korea-based company mainly engaged in the production and sale of veterinary drugs. The Company operates its business through two segments. The Sale Business segment is involved in the provision of livestock disease appraisal services, animal drug distribution, and the manufacturing and sale of feed additives. The New Business segment is engaged in research and development of heterologous organisms, virus like particle (VLP) vaccines, and human diagnostic kits. Heterogeneous organ products include heterologous skin, xenogeneic islets and xenogeneic corneal products, among others. VLP vaccines include VLP based animal combined vaccines and human papillomavirus (HPV) vaccines for the human body, among others. Human body diagnostic kits include human breast cancer and cervical cancer diagnostic reagents, among others. The Company distributes its products within the domestic market and to overseas markets.
(Source: N-30D)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Co-Chief Executive Officer, Director Seong JunHan 49 4/4/2019 4/4/2019
Co-Chief Executive Officer, Director Hyeon YilKim 46 4/4/2019 4/4/2019

General Information
Number of Employees: 77 (As of 12/31/2023)
Outstanding Shares: 14,669,958 (As of 12/31/2023)
Shareholders: 9,517
Stock Exchange: KDQ
Fax Number: +82 432497501


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 18, 2024